Clinical trials: Cohort Study
Child, Preschool, Child
Monitoring Activity And Gait In Children
COHORT A: To study whether a digital health tool called Actigraph can be used to collect information on gait and physical activity in healthy children aged 3-17.
- Conditions
- Child, Preschool, Child, Adolescent
- Trial name
- MAGIC (NCT04823650)
- Testing
- COHORT A: Actigraph, Panoramic Bracelet and GENEActiv
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Pfizer
Leukemia, Myeloid, Acute
BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse
Patients with acute myeloid leukemia who experience a relapse after at least one prior regimen may be enrolled in this trial. In addition, acute myeloid leukemia patients who are in complete remission with high risk to relapse…
- Trial name
- NCT01690624
- Testing
- BI 836858
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Colorectal Cancer
Cohort Study to Evaluate the Relapse Risk Test in Colorectal Cancer
A Retrospective Cohort Study to Evaluate a Multigene assay to assess the recurrence risk of colorectal cancer.
- Trial name
- NCT05115786
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- HBI Solutions Inc.
Alzheimer's Disease, Mild Cognitive Impairment
Diagnosis and Monitoring of Disease Progression Using Deep Neuro Signatures
Alzheimer's disease (AD) clinically characterized by the cognitive impairment and lowering of various functional abilities lead to staggering costs and suffering, which are particularly related to the social impacts of caring for…
- Trial name
- DNS (NCT05153941)
- Where
- Greece
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Altoida
Neurofibromatosis Type 1
PASS of Paediatric Patients Initiating Selumetinib
Neurofibromatosis type 1 (NF1) is a rare, autosomal dominant genetic disorder that is caused by germline mutations in the NF1 tumour suppressor gene, which encodes the tumour suppressor protein neurofibromin 1.
- Trial name
- NCT05388370
- Where
- 46 sites in Austria, France and 8 more
- Volunteers
- 124 people
- Sponsor
- AstraZeneca
Solid Tumor, Advanced Cancer
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor
This is a Phase 1, open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study with cohort expansion at the RP2D to evaluate safety and anti- tumor activity of Q702 administered…
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer
- Trial name
- NCT04648254
- Testing
- Q702
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Qurient Co., Ltd.
Cancer
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of daily oral administration of eFT508.
- Trial name
- NCT02605083
- Testing
- eFT508
- Where
- 4 sites in United States
- Volunteers
- 66 people
- Sponsor
- Effector Therapeutics
Genetic Disease, Nonsense Mutation
Phase 1 Study of ELX-02 in Healthy Adult Subjects
Phase 1 Multiple Ascending Dose Study in Normal Healthy Volunteers
- Trial name
- NCT03309605
- Testing
- ELX-02
- Where
- Belgium
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Eloxx Pharmaceuticals, Inc.
Influenza
A Prospective Epidemiological Cohort Study Evaluating Occurrences of Influenza-like Illness.
This Prospective epidemiological cohort study is being conducted in order to generate epidemiological data in support of Osivax's clinical development of a broad spectrum influenza vaccine based upon the internal influenza…
- Trial name
- NCT05184387
- Testing
- Blood samples
- Where
- Belgium
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Osivax
Melanoma
Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-145 (JSC BIOCAD, Russia) Monotherapy in Patients with Unresectable/Metastatic Melanoma.
- Trial name
- NCT03472027
- Testing
- BCD-145
- Where
- 4 sites in Russia
- Volunteers
- 15 people
- Sponsor
- Biocad
HER2-positive Newly Diagnosed, Primary Breast Cancer
NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer
This randomized, parallel cohort, two stage, double-blind, placebo-controlled study evaluated the oral PI3K inhibitor BKM120 in combination with trastuzumab and paclitaxel in HER2-positive, PIK3CA wild-type and PIK3CA mutant…
- Trial name
- NeoPHOEBE (NCT01816594)
- Testing
- BKM120, Trastuzumab, Paclitaxel
- Where
- 7 sites in Australia, Austria and 2 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
The goal of the study is to evaluate the safety and tolerability of ACR246 in patients with advanced solid tumors, to determine the maximum tolerated dose (MTD) and Phase II recommended dose (RP2D) of ACR246.
- Trial name
- NCT06238401
- Testing
- ACR246 for injection
- Where
- 6 sites in China
- Volunteers
- 77 people
- Sponsor
- Hangzhou Adcoris Biopharmacy Co., Ltd
HIV-1-infection
Study of GS-3242 in Participants With HIV-1; Substudy-05
This study is part of a master study. The goal of master protocol (GS-US-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1…
- Trial name
- NCT07001319
- Testing
- GS-3242, BVY, Standard of Care
- Where
- 28 sites in United States, Mexico and 1 more
- Volunteers
- 27 people
- Sponsor
- Gilead Sciences
Phenylketonuria
Response to Kuvan® in Subjects With Phenylketonuria (PKU) in a 4 Weeks Testing Period
The primary objective of the study is to evaluate the proportion of responders (that is, greater than or equal to [>=] 30 percent reduction from Baseline in blood phenylalanine [Phe] level) to treatment with Kuvan® (sapropterin…
- Trial name
- ENDURE (NCT01082328)
- Testing
- Kuvan®
- Where
- Norway
- Volunteers
- 59 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Whooping Cough
The Safety of Boostrix Following Routine Immunization of Pregnant Women
The purpose of this study was to assess the safety of Boostrix administered on or after the first day of the 27th week of pregnancy by conducting a post-marketing study that provided safety information to the public and…
- Trial name
- NCT03463577
- Testing
- Safety assessment following routine immunization with Boostrix
- Where
- United States
- Volunteers
- 65,783 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Musculoskeletal Pain
Study to Evaluate EB-001 in Reducing Musculoskeletal Pain
To determine the safety and efficacy of single intra-operative treatment of EB-001 IM injections into the Pectoralis Major (PM) in subjects undergoing breast augmentation with subpectoral implants
- Trial name
- NCT03193593
- Testing
- EB-001
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Bonti, Inc.
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received…
- Trial name
- EvoPAR-PR05 (NCT07711002)
- Testing
- Saruparib, Enzalutamide, Darolutamide
- Where
- 210 sites in United States, Austria and 19 more
- Volunteers
- 1,330 people
- Sponsor
- AstraZeneca
Medical Prevention Therapy
Canadian Outpatient VTE Management Registry
Primary Objective: To obtain prospective, clinical practice-based data on how symptomatic VTE is managed with low molecular weight heparin (LMWH) enoxaparin in Canadian outpatient settings.
- Trial name
- RECOVERY (NCT01133002)
- Where
- Canada
- Volunteers
- 915 people
- Sponsor
- Sanofi
SARS-CoV-2
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
The goal of this study is to confirm the onset status of hypersensitivity reactions including shock and anaphylaxis observed after vaccination with this drug in persons with underlying diseases who are considered to have a high…
- Trial name
- NCT05894499
- Where
- Japan
- Volunteers
- 13,309 people
- Sponsor
- ModernaTX, Inc.
Non-small Cell Lung Cancer
RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada
In the RELEVANCE study, we will develop a scalable electronic medical report data capture platform to collect and analyse real-world data in the stage III NSCLC population in Canada across several Canadian cancer centres.
- Trial name
- RELEVANCE (NCT05933044)
- Testing
- Durvalumab
- Where
- 5 sites in Canada
- Volunteers
- 662 people
- Sponsor
- AstraZeneca